SRSF1
Basic information
Region (hg38): 17:58000919-58007346
Previous symbols: [ "SFRS1" ]
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Musculoskeletal; Neurologic | 37071997 |
ClinVar
This is a list of variants' phenotypes submitted to
- Neurodevelopmental delay;Intellectual disability (10 variants)
- Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities (4 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SRSF1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 9 | |||||
nonsense | 5 | |||||
start loss | 0 | |||||
frameshift | 3 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 10 | 0 | 7 | 0 | 0 |
Variants in SRSF1
This is a list of pathogenic ClinVar variants found in the SRSF1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-58005420-G-A | Inborn genetic diseases | Uncertain significance (Feb 28, 2023) | ||
17-58005551-CT-C | Neurodevelopmental delay;Intellectual disability | Pathogenic (Feb 15, 2023) | ||
17-58005573-C-CT | Neurodevelopmental delay;Intellectual disability • Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities | Pathogenic (Feb 15, 2023) | ||
17-58005800-C-A | Inborn genetic diseases | Likely pathogenic (Sep 19, 2024) | ||
17-58005805-T-C | Neurodevelopmental delay;Intellectual disability | Uncertain significance (Feb 15, 2023) | ||
17-58005875-C-T | Neurodevelopmental delay;Intellectual disability • Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities | Pathogenic/Likely pathogenic (Mar 19, 2024) | ||
17-58005890-C-T | Inborn genetic diseases | Uncertain significance (Jun 11, 2024) | ||
17-58005893-G-A | Inborn genetic diseases | Uncertain significance (Mar 12, 2024) | ||
17-58005895-T-A | Inborn genetic diseases | Uncertain significance (Mar 30, 2024) | ||
17-58005923-C-T | Uncertain significance (Jun 14, 2024) | |||
17-58006343-CAG-C | Neurodevelopmental delay;Intellectual disability | Pathogenic (Feb 15, 2023) | ||
17-58006354-ACT-A | Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities | Likely pathogenic (Sep 20, 2024) | ||
17-58006433-G-A | Uncertain significance (Oct 21, 2016) | |||
17-58006471-A-C | Neurodevelopmental delay;Intellectual disability • Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities | Pathogenic (Feb 15, 2023) | ||
17-58006481-C-T | Uncertain significance (Oct 31, 2023) | |||
17-58006491-A-C | Neurodevelopmental delay;Intellectual disability | Pathogenic (Feb 15, 2023) | ||
17-58006513-G-A | Inborn genetic diseases | Uncertain significance (Mar 11, 2024) | ||
17-58006514-C-T | Neurodevelopmental delay;Intellectual disability | Pathogenic (Feb 15, 2023) | ||
17-58007008-C-T | Neurodevelopmental delay;Intellectual disability | Uncertain significance (Feb 16, 2023) | ||
17-58007019-C-A | Neurodevelopmental delay;Intellectual disability • Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities | Pathogenic (Feb 15, 2023) | ||
17-58007030-G-C | Uncertain significance (Apr 15, 2024) | |||
17-58007041-C-A | Neurodevelopmental delay;Intellectual disability | Pathogenic (Feb 15, 2023) | ||
17-58007056-G-A | Neurodevelopmental delay;Intellectual disability | Pathogenic (Feb 15, 2023) | ||
17-58007061-T-G | Inborn genetic diseases | Uncertain significance (Apr 11, 2024) | ||
17-58007067-G-A | Neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities • Intellectual disability;Neurodevelopmental delay | Conflicting classifications of pathogenicity (Feb 15, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SRSF1 | protein_coding | protein_coding | ENST00000258962 | 4 | 3987 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.983 | 0.0173 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.96 | 22 | 165 | 0.133 | 0.00000878 | 1585 |
Missense in Polyphen | 1 | 43.296 | 0.023097 | 478 | ||
Synonymous | -0.254 | 59 | 56.6 | 1.04 | 0.00000260 | 527 |
Loss of Function | 3.26 | 0 | 12.4 | 0.00 | 6.87e-7 | 124 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Plays a role in preventing exon skipping, ensuring the accuracy of splicing and regulating alternative splicing. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Can stimulate binding of U1 snRNP to a 5'-splice site-containing pre-mRNA. Binds to purine-rich RNA sequences, either the octamer, 5'-RGAAGAAC-3' (r=A or G) or the decamers, AGGACAGAGC/AGGACGAAGC. Binds preferentially to the 5'- CGAGGCG-3' motif in vitro. Three copies of the octamer constitute a powerful splicing enhancer in vitro, the ASF/SF2 splicing enhancer (ASE) which can specifically activate ASE-dependent splicing. Isoform ASF-2 and isoform ASF-3 act as splicing repressors. May function as export adapter involved in mRNA nuclear export through the TAP/NXF1 pathway. {ECO:0000269|PubMed:8139654}.;
- Pathway
- IL-17 signaling pathway - Homo sapiens (human);Spliceosome - Homo sapiens (human);Herpes simplex infection - Homo sapiens (human);mRNA Processing;Gene expression (Transcription);RNA Polymerase II Transcription;Metabolism of RNA;Cleavage of Growing Transcript in the Termination Region ;RNA Polymerase II Transcription Termination;mRNA Splicing - Major Pathway;Transport of Mature mRNA derived from an Intron-Containing Transcript;mRNA Splicing - Minor Pathway;mRNA Splicing;mRNA 3,-end processing;Transport of Mature Transcript to Cytoplasm;Processing of Capped Intron-Containing Pre-mRNA
(Consensus)
Recessive Scores
- pRec
- 0.0447
Intolerance Scores
- loftool
- rvis_EVS
- -0.01
- rvis_percentile_EVS
- 52.85
Haploinsufficiency Scores
- pHI
- 0.851
- hipred
- Y
- hipred_score
- 0.748
- ghis
- 0.660
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.539
Mouse Genome Informatics
- Gene name
- Srsf1
- Phenotype
- cellular phenotype; muscle phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); vision/eye phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- alternative mRNA splicing, via spliceosome;regulation of alternative mRNA splicing, via spliceosome;mRNA 5'-splice site recognition;mRNA splicing, via spliceosome;in utero embryonic development;mRNA splice site selection;mRNA processing;RNA export from nucleus;mRNA export from nucleus;mRNA 3'-end processing;positive regulation of RNA splicing;mRNA cis splicing, via spliceosome;oligodendrocyte differentiation;cardiac muscle contraction;liver regeneration
- Cellular component
- nucleus;nucleoplasm;cytoplasm;nuclear speck;exon-exon junction complex;catalytic step 2 spliceosome
- Molecular function
- RNA binding;mRNA binding;protein binding;protein kinase B binding;DNA topoisomerase binding;RS domain binding